Children's Hospital of Philadelphia collaborates in gene therapy success in an immune disorder

November 16, 2010

A pediatric immunologist at The Children's Hospital of Philadelphia collaborated with European gene therapy researchers who achieved marked clinical improvements in two young children with Wiskott-Aldrich syndrome, a very rare but often severe immunodeficiency disorder.

Jordan S. Orange, M.D., Ph.D., an expert in Wiskott-Aldrich syndrome (WAS), performed sophisticated cell imaging and analysis for the study, led by German researcher Christoph Klein, M.D., Ph.D., of Hannover Medical School. Orange was a senior co-author, and Children's Hospital was the only U.S. institution represented in the study, published in the Nov. 11 New England Journal of Medicine.

The proof-of-principle study marks the latest example of a recent upswing in clinical success for gene therapy. In 2009, researchers from The Children's Hospital of Philadelphia and the University of Pennsylvania reported dramatic vision improvements in patients with Leber congenital amaurosis (LCA), a form of inherited blindness. In the same year, Parisian researchers announced success in treating adrenoleukodystrophy, the disease depicted in the movie "Lorenzo's Oil." And scientists at the University of California are reporting preliminary clinical benefits in gene therapy for adenosine deaminase deficiency, an immune deficiency disorder related to "bubble boy disease."

Like WAS, all are very rare inherited disorders and have the potential to be severe and (except for LCA) life-threatening.

Wiskott-Aldrich syndrome is a complex X-linked immunodeficiency disorder characterized by recurrent infections, eczema and thrombocytopenia-a low platelet count. Mutations in the WAS gene disable its ability to produce WAS protein, which plays a crucial role in different types of immune cells. Without WAS protein, immune cells are disabled, incapable of providing immune defenses. Hence, patients are susceptible to premature death from infection, cancers or bleeding.

Although WAS has a range of severity, the only current cure is stem cell transplantation, which carries its own risks.

In the current study, based in Germany, the research team treated both children, three-year-old boys diagnosed with WAS soon after birth, by first collecting some of their hematopoietic (blood cell-forming) stem cells. They then transferred normal WAS genes into those cells and returned the cells to the boys' bloodstreams.

After treatment, the patients experienced fewer and less severe infections. Bleeding episodes decreased after platelet counts improved. Severe autoimmune anemia disappeared in one boy and severe eczema completely resolved in the other. Three years after the gene therapy, treatment-limiting adverse effects had not occurred, and the clinical benefits persisted. Significantly, the researchers reported that the treatment corrected thrombocytopenia, a hazardous and difficult-to-treat complication of WAS.

On reporting encouraging results in the first two children, the researchers noted the need to expand the study to additional patients, while conducting longer-term follow-up and analysis.

The study team found increased levels of the normal WAS protein expressed by the gene they had introduced. Orange's laboratory at Children's Hospital performed analytic imaging studies that provided evidence that the corrected immune cells were functioning normally. "Our highly quantitative imaging studies assessed natural killer cells, a critically disabled immune cell in Wiskott-Aldrich patients, and demonstrated a remarkable return to normality after gene therapy," Orange said.

Orange Translates Basic Science to Possible Immunotherapy for WAS

Orange drew on his deep background in investigating how natural killer cells function in the immune system. While a graduate student, in 1996, he discovered that natural killer cells produce cytokines, important signaling proteins, to participate in immune defense against viruses. Over the past decade he has defined the field of human natural killer cell deficiencies in various genetic disorders.

At Children's Hospital, where he treats patients, Orange is investigating a treatment for WAS distinct from gene therapy. In a current clinical trial in WAS, his immunotherapy approach bypasses the gene defect in the disease, instead using the cytokine IL-2 to boost immune function. He expects to publish initial results shortly.

"If our immunotherapy approach is safe and effective, it may represent a treatment for the full spectrum of WAS patients," he said, noting that the gene therapy trial is currently limited to the most severe cases. "Even patients with less severe WAS are at risk for lymphoma and other blood cell cancers, so broadening treatment options would be an important advance in treatment."

Children's Hospital of Philadelphia

---

---

	The Forever Fix: Gene Therapy and the Boy Who Saved It by Ricki Lewis (Author) Fascinating narrative science that explores the next frontier in medicine and genetics through the very personal prism of the children and families gene therapy has touched.Eight-year-old Corey Haas was nearly blind from a hereditary disorder when his sight was restored through a delicate procedure that made medical history.  Like something from a science fiction novel, doctors carefully injected viruses bearing healing genes into the DNA of Corey's eyes—a few days later, Corey could see, his sight restored by gene therapy.THE FOREVER FIX is the first book to tell the fascinating story of gene therapy: how it works, the science behind it, how patients (mostly children) have been helped and harmed, and how scientists learned from each trial to get one step closer to its immense...
	A Guide to Human Gene Therapy by Roland W. Herzog (Author), Roland W. Herzog (Editor), Sergei Zolotukhin (Editor) Ever since the birth of molecular biology, the tantalizing possibility of treating disease at its genetic roots has become increasingly feasible. Gene therapy though still in its infancy remains one of the hottest areas of research in medicine. Its approach utilizes a gene transfer vehicle ("vector") to deliver therapeutic DNA or RNA to cells of the body in order to rectify the defect that is causing the disease. Successful therapies have been reported in humans in recent years such as cures in boys with severe immune deficiencies. Moreover, gene therapy strategies are being adapted in numerous biomedical laboratories to obtain novel treatments for a variety of diseases and to study basic biological aspects of disease. Correction of disease in animal studies, is steadily gaining ground,...
	Gene Therapy by Mauro Giacca (Author) The overall purpose of this book is to expose the reader/student to a comprehensive and detailed, yet still easily accessible, overview of the whole field of gene therapy, ranging from vector development and therapeutic gene selection to the results of the most recent clinical trials. The language is plain and, whenever possible, non-technical. Since the book is intended to be a textbook in the field of gene therapy in both the basic science and clinical areas, when technical descriptions are required, they are provided either in the main text or in add-on explanatory boxes. For example, clinical readers might find it difficult to understand the principles of viral vector design without knowing some molecular details of viral genome organization and virus life cycle, and basic scientists...
	Gene Therapy by Mary Colavito (Author), Michael A. Palladino (Author) KEY MESSSAGE: Will gene therapy one day become the ultimate application of genetic technology?  Gene Therapy, the newest booklet in the Special Topics in Biology Series, addresses this question by exploring gene therapy as a complex technology for delivering therapeutic genes as a way to treat and cure human genetic diseases. Author Mary Colavito provides an overview of the basic science involved in gene therapy methods and chronicles the history of gene therapy by discussing successful and ongoing gene therapy treatments as well as adverse outcomes in some cases of gene therapy. Also discussed are challenges that must be overcome for gene therapy to become a more reliable and readily accessible approach for treating a multitude of genetic diseases that affect humans. Gene Therapy:...
	Gene Therapy: Treatments and Cures for Genetic Diseases (New Biology) by Joseph Panno (Author)
	Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, Third Edition by Nancy Smyth Templeton (Author), Danilo D. Lasic (Author), Nancy Smyth Templeton (Editor) Since the publication of the second edition of this book in 2004, gene therapy and cell therapy clinical trials have yielded some remarkable successes and some disappointing failures. Now in its third edition, Gene and Cell Therapy: Therapeutic Mechanisms and Strategies assembles many of the new technical advances in gene delivery, clinical applications, and new approaches to the regulation and modification of gene expression. New Topics Covered in this Edition: Gene and Cell Therapies for Diabetes and Cardiovascular Diseases Clinical Trials Human Embryonic Stem Cells Tissue Engineering Combined with Cell Therapies Novel Polymers Relevant Nanotechnologies SiRNA Therapeutic Strategies Dendrimer Technologies Comprised of contributions from...
	Gene Therapy Research (Inside Science) by Hal Marcovtiz (Author)
	Gene Therapy and Gene Delivery Systems (Advances in Biochemical Engineering Biotechnology) by David V. Schaffer (Editor), Weichang Zhou (Editor) 1 D.V. Schaffer, W. Zhou: Gene Therapy as Future Human Therapeutics.- 2 J. Heidel, S. Mishra, M.E. Davis: Molecular Conjugates.- 3 M. Manthorpe, P. Hobart, G. Hermanson, M. Ferrari, A. Geall, B. Goff, A. Rolland: Plasmid Vaccines and Therapeutics: From Design to Applications.- 4 S.R. Little, R. Langer: Non-Viral Delivery of Cancer Genetic Vaccines.- 5 J.C. Grieger, R.J. Samulski: Adeno-Associated Virus as a Gene Therapy Vector: Vector Development, Production and Clinical Applications.- 6 J.H. Yu, D.V. Schaffer: Advanced Targeting Strategies for Murine Retroviral and Adeno-Associated Viral Vectors.- 7 N. Loewen, E.M. Poeschla: Lentiviral Vectors.- 8 N.E. Altaras, J.G. Aunins, R.K. Evans, A. Kamen, J.O. Konz, J.J. Wolf: Production and Formulation of Adenovirus Vectors.-
	Gene Therapy: Treating Disease by Repairing Genes (The New Biology) by Joseph Panno (Author) Gr. 9-12. The science and technology are detailed, dense, accurate, and up-to-date in this title in the New Biology series, and the readable discussion of the ethical issues shows that there are no simple answers. Physiologist Panno explains how stem cells can be used to treat, and possibly cure, a wide variety of diseases, and he predicts that the use of adult stem cells will soon be routine. An important chapter looks at legal practices in the U.S., Europe, and the U.K. The book includes occasional diagrams; an extensive, detailed glossary; and many bibliographical references to science and ethical discussions in print and on the Web. In addition, there is a chapter summarizing cell biology and recombinant DNA technology. A carefully done, in-depth series that will work well for...
	Cell Therapy: cGMP Facilities and Manufacturing by Adrian Gee (Editor) Cell Therapy: cGMP Facilities and Manufacturing is the source for a complete discussion of facility design and operation with practical approaches to a variety of day-to-day activities, such as staff training and competency, cleaning procedures, and environmental monitoring. This in-depth book also includes detailed reviews of quality, the framework of regulations, and professional standards. It meets a previously unmet need for a thorough facility-focused resource, Cell Therapy: cGMP Facilities and Manufacturing will be an important addition to the cell therapy professional’s library. Additional topics in Cell Therapy: cGMP Facilities and Manufacturing…Standard operating procedures - Supply management - Facility equipment - Product manufacturing, review, release and administration -...